We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Apexigen announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.
California biotech Apexigen has raised $73 million from a pair of financings that will be used for clinical testing of its lead CD40-targeting immuno-oncology candidate as well as to broaden its pipeline.